Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.46 |
| ▸ | CYP51A1 | Q16850 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.45 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.44 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2278489 | 0.83 | SSTR3 (0.54) | SSTR3VCPGID4HRH3CHRNA7 | |
| SCHEMBL22604095 | 0.79 | SSTR3 (0.57) | SSTR3METTL3METTL14HRH3 | |
| SCHEMBL377906 | 0.76 | DRD4 (0.64) | DRD4 | |
| SCHEMBL25183371 | 0.76 | HRH4 (0.66) | DRD4HRH3 | |
| SCHEMBL18047025 | 0.75 | HDAC1 (0.52) | SSTR3VCPGID4METTL3METTL14 | |
| SCHEMBL18047024 | 0.75 | HDAC1 (0.52) | SSTR3VCPGID4METTL3METTL14 | |
| SCHEMBL4270492 | 0.75 | SLC2A1 (0.50) | DRD4IDO1 | |
| SCHEMBL3492387 | 0.73 | IDO1 (0.42) | SSTR3METTL3METTL14IDO1 | |
| SCHEMBL7448002 | 0.72 | HRH3 (0.48) | SSTR3DRD4VCPHRH3CHRNA7 | |
| SCHEMBL3494336 | 0.72 | IDO1 (0.41) | SSTR3METTL3METTL14IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534793-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2009-05-19 | — | — | US | claimed |
| EP-1305308-B1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2006-12-20 | — | — | EP | claimed |
| US-20060014749-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. | 2006-01-19 | — | — | US | claimed |
| US-7534793-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2009-05-19 | — | — | US | disclosed |
| EP-1305308-B1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2006-12-20 | — | — | EP | disclosed |
| US-20060014749-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM P.L.C. | 2006-01-19 | — | — | US | disclosed |
| US-6962917-B2 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-11-08 | — | — | US | disclosed |
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | disclosed |
| CN-1452619-A | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | SMITHKLINE BEECHAM PLC (GB) | 2003-10-29 | — | — | CN | disclosed |
| EP-1305308-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002008224-A1 | AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038998-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterical activity | AZI2, AMPD2, AMPD1 | SSTR3 4492/4885DRD4 431/4885VCP 3297/4885 |
| US-20060014749-A1 | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity | AZI2, NPEPPS, AMPD2 | SSTR3 4050/4885DRD4 560/4885VCP 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.